Evidence-Based Complementary and Alternative Medicine / 2019 / Article / Tab 2

Research Article

Safety and Efficacy of the C-117 Formula for Vulnerable Carotid Artery Plaques (Spchim): A Randomized Double-Blind Controlled Pilot Study

Table 2

Baseline characteristics.

C-117 formula groupPlacebo group
(n=59) (n=59)

Basic Features

Age (Yr) 64.76 ± 7.07963.5 ± 7.691
≥60, n (%)46(78.0%)43(72.9%)
Gender
 Female34(57.6%)28(47.5%)
 Male25(42.4%)31(52.5%)
Height (cm) 161.39 ± 7.8162.46 ± 6.18
Weight (kg) 62.92 ± 11.062.13 ± 8.58
Systolic blood pressure, , (mmHg)126.29 ± 11.33127.56 ± 13.85
Diastolic blood pressure, , (mmHg)71.88 ± 8.8174.32 ± 11.37

Past history, n (%)

Ischemic stroke or TIA8(13.6%)9(15.3%)
Diabetes14(23.7%)13(22.0%)
Hypertension30(50.8%)37(62.7%)
Hyperuricemia6(10.2%)5(8.5%)
Other medical history30(50.8%)31(52.5%)

Personal life history, n (%)

Exercise
 Often33(55.9%)36(61.0%)
 Occasionally26(44.1%)22(37.3%)
 Never0(0%)1(1.75%)
Eat vegetables every day55(93.2%)52(88.1%)
Eat fruit every day35(59.3%)34(57.6%)
Smoking history7(11.9%)9(15.3%)
Drinking history19(32.2%)11(18.6%)

Taking lipid-lowering drugs, n (%)

Atorvastatin calcium tablets48(81.4%)46(78.0%)
Other lipid-lowering drugs10(16.9%)10(16.9%)
Not taken1(1.7%)3(5.1%)

Combination therapy, n (%)

Antihypertensive drugs28(47.5%)30(50.8%)
Hypoglycaemic agents10(16.9%)11(18.6%)
Antiplatelet drug12(20.3%)9(15.3%)
Other medication20(33.9%)12(20.3%)

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.